BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30892689)

  • 21. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
    Quresh Q; Quinet R
    J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
    [No Abstract]   [Full Text] [Related]  

  • 22. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
    Wernham AGH; Shah F; Velangi S
    Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
    [No Abstract]   [Full Text] [Related]  

  • 23. Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.
    Prasanna T; McNeil CM; Nielsen T; Parkin D
    Immunotherapy; 2018 Mar; 10(3):171-175. PubMed ID: 29370723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy.
    Apostolova P; Unger S; von Bubnoff D; Meiss F; Becher B; Zeiser R
    N Engl J Med; 2020 Jan; 382(3):294-296. PubMed ID: 31940706
    [No Abstract]   [Full Text] [Related]  

  • 25. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diarrhoea during checkpoint blockade, not always colitis.
    Koldenhof JJ; Suijkerbuijk KPM
    Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
    [No Abstract]   [Full Text] [Related]  

  • 27. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series.
    Zheng J; Irani Z; Lawrence D; Flaherty K; Arellano RS
    J Vasc Interv Radiol; 2018 Oct; 29(10):1369-1375. PubMed ID: 30174161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
    Franklin C; Rooms I; Fiedler M; Reis H; Milsch L; Herz S; Livingstone E; Zimmer L; Schmid KW; Dittmer U; Schadendorf D; Schilling B
    Eur J Cancer; 2017 Nov; 86():248-256. PubMed ID: 29055840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipilimumab prolongs survival in advanced melanoma.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e481. PubMed ID: 27746107
    [No Abstract]   [Full Text] [Related]  

  • 30. Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis.
    Herlihy JD; Beasley S; Simmelink A; Maddukuri V; Amin A; Kamionek M; Jacobs C; Bossi K; Scobey M
    South Med J; 2019 Mar; 112(3):154-158. PubMed ID: 30830228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
    Warner AB; Postow MA
    Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Some points on the diagnosis of microscopic colitis].
    Torres Gómez FJ
    Gastroenterol Hepatol; 2015 Jan; 38(1):40-1. PubMed ID: 25128380
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
    Algazi AP; Tsai KK; Shoushtari AN; Munhoz RR; Eroglu Z; Piulats JM; Ott PA; Johnson DB; Hwang J; Daud AI; Sosman JA; Carvajal RD; Chmielowski B; Postow MA; Weber JS; Sullivan RJ
    Cancer; 2016 Nov; 122(21):3344-3353. PubMed ID: 27533448
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microscopic colitis and endoscopy.
    Koulaouzidis A
    Neth J Med; 2009 Oct; 67(9):316. PubMed ID: 19841492
    [No Abstract]   [Full Text] [Related]  

  • 35. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
    Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
    Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
    [No Abstract]   [Full Text] [Related]  

  • 36. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
    Chiarion Sileni V; Mandalà M; Queirolo P
    Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
    Nardin C; Pelletier F; Puzenat E; Aubin F
    Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
    [No Abstract]   [Full Text] [Related]  

  • 38. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
    Suarez-Almazor ME; Kim ST; Abdel-Wahab N; Diab A
    Arthritis Rheumatol; 2017 Apr; 69(4):687-699. PubMed ID: 28085999
    [No Abstract]   [Full Text] [Related]  

  • 39. Programmed cell death 1 blockade-induced cutaneous sarcoid-like epithelioid granulomas in advanced melanoma: a case report.
    Ogawa T; Ishitsuka Y; Iwamoto K; Koguchi-Yoshioka H; Tanaka R; Watanabe R; Fujisawa Y; Fujimoto M
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e260-e261. PubMed ID: 29314333
    [No Abstract]   [Full Text] [Related]  

  • 40. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers.
    Liu RC; Consuegra G; Chou S; Fernandez Peñas P
    Clin Exp Dermatol; 2019 Aug; 44(6):643-646. PubMed ID: 30618056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.